Want to know what's happening next in healthcare?

MedCityNews is the leading online news source for the business of innovation in healthcare.

“I find MedCity News a great resource for taking the pulse of the market and sourcing potential investment opportunities.”

Bernie Rudnick, Angel investor and advisor, CapGenic Advisors, LLC

Sign up for our daily newsletter

Amarin waits for FDA OK on marketing exclusivity for Lovaza competitor Vascepa

6:05 pm by | 0 Comments

(Reuters) - Amarin Corp said the U.S. health regulator is yet to decide on granting exclusive marketing rights to its heart drug Vascepa, sending its shares down 3 percent In extended trading.

Based on its talks with the U.S. Food and Drug Administration, Amarin does not expect the FDA's Orange Book Supplement to include an entry with respect to the regulatory exclusivity status of Vascepa. the company said.

The FDA publishes an Orange Book, which includes details of recently approved products, patent and exclusivity information.

Vascepa, which would compete with GlaxoSmithKline Plc's Lovaza, serves as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia.


Shares of the Ireland-based company were down at $14 in extended trading. They closed at $14.41 on the Nasdaq on Monday.

Copyright 2014 MedCity News. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Hear the latest news first

Get our daily newsletter or follow us.